Thymostimulin effects on the pituitary-ovarian axis in hyperprolactinemic young female rats. 1995

M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
Departamento de Bioquímica, Facultad de Medicina, Universidad Complutense de Madrid, España.

This work was undertaken to study the effects of thymostimulin on the pituitary-ovarian axis of young female rats, and to elucidate possible prolactin-mediated effects. 30-day-old rats implanted with an ectopic pituitary from a littermate male donor under the kidney capsule or sham-operated animals were injected with thymostimulin or vehicle for 2 and 8 days. Chronic thymostimulin treatment to sham-operated rats increased plasma prolactin and estradiol levels, and decreased gonadotropin levels. Thymostimulin administration to pituitary-grafted rats did not further modify the increase in plasma prolactin and the decrease in plasma luteinizing hormone levels induced by the presence of an ectopic pituitary, suggesting a hypothalamic and/or hypophysial site of action of the thymic fraction. An increase in plasma estradiol and progesterone levels was observed with the in vivo thymostimulin treatment, although differential in vitro effects on estradiol responses to human chorionic gonadotropin in the various groups studied were observed. These effects seem to be mediated through the changes in plasma prolactin and gonadotropin concentrations observed. The above-mentioned changes induced by the thymic fraction on plasma estradiol and progesterone levels might counteract prolactin effects on the thymus. These data suggest that thymostimulin treatment of young female rats changes hypophysial and sex hormone secretion, as well as the response of the ovaries to human chorionic gonadotropin, probably modifying the normal process of sexual maturation.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D007369 Interferon Inducers Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. Inducers, Interferon
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D008297 Male Males
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D010902 Pituitary Gland A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM. Hypophysis,Hypothalamus, Infundibular,Infundibular Stalk,Infundibular Stem,Infundibulum (Hypophysis),Infundibulum, Hypophyseal,Pituitary Stalk,Hypophyseal Infundibulum,Hypophyseal Stalk,Hypophysis Cerebri,Infundibulum,Cerebri, Hypophysis,Cerebrus, Hypophysis,Gland, Pituitary,Glands, Pituitary,Hypophyseal Stalks,Hypophyses,Hypophysis Cerebrus,Infundibular Hypothalamus,Infundibular Stalks,Infundibulums,Pituitary Glands,Pituitary Stalks,Stalk, Hypophyseal,Stalk, Infundibular,Stalks, Hypophyseal,Stalks, Infundibular
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females

Related Publications

M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
May 2020, Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
July 2014, Reproductive toxicology (Elmsford, N.Y.),
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
December 2021, Ecotoxicology and environmental safety,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
February 1995, The Journal of clinical endocrinology and metabolism,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
January 2014, General physiology and biophysics,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
August 1992, Journal of pineal research,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
January 1978, Journal of endocrinological investigation,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
November 2017, Journal of the Endocrine Society,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
January 2008, Pituitary,
M L Moreno, and C Agrasal, and M A Villanúa, and M Giordano, and A I Esquifino
March 1983, Acta endocrinologica,
Copied contents to your clipboard!